Immunization Safety Review: Vaccines and Autism

Questions? Call 800-624-6242

About | Ordering | New

LoginRegister

| Items in cart [0]

PAPERBACK
price:$39.00
add to cart

Rights & Permissions

Free PDF Access

Free Resources

Related Titles

Immunization Safety Review: Vaccines and Autism (2004)
Board on Health Promotion and Disease Prevention (HPDP)
Institute of Medicine (IOM)

Citation Manager Export the bibliographic data for this book in your chosen format
Web Search Builder Use this book's key terms to search within this book, across our collection, or across the Web.
Skim This Chapter Skim this chapter and use this chapter's key terms to search within this book.
Reference Finder Paste in your own text to find books that relate to your topic.

Citation Manager

. "Appendix C: Thimerosal Content in Licensed Vaccines." Immunization Safety Review: Vaccines and Autism. Washington, DC: The National Academies Press, 2004.

Please select a format:

Page
184


E-mail Share on facebook Facebook Share on delicious Delicious Share on stumbleupon Stumble Share on twitter Twitter More Sharing ServicesMore

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.

Immunization Safety Review: Vaccines and Autism

TABLE C-1 Mercury Content from Thimerosal in the Routinely Recommended Pediatric Vaccines¹ in the United States, April 2004

Vaccine	Brand Name	Manufacturer	Hg [μg/dose]
DTaP (Diphtheria and tetanus toxoids and acellular pertussis)	Tripedia	Aventis Pasteur, Inc.	≤0.3
	Infanrix	Glaxo-SmithKline	0
	Daptacel	Aventis Pasteur, Ltd	0
Td¹ (Tetanus and diphtheria toxoids)	None	Aventis Pasteur, Inc.	25
	Decavac	Aventis Pasteur, Inc.	= 0.3
	None	Aventis Pasteur, Ltd	0
	None	Mass Public Health	8.3
DTaP-Hib (Diphtheria and tetanus toxoids with acellular pertussis combined with Haemophilus influenzae type b)	TriHIBit²	Aventis Pasteur	≤0.3
Hib (Haemophilus influenzae type b)	ActHIB/OmniHib	Aventis Pasteur, SA	0
	HibTITER (Single dose)	Wyeth-Lederle	0
	PedvaxHIB liquid	Merck	0
Hib/HepB (Haemophilus influenzae type b combined with Hepatitis B )	COMVAX	Merck	0
Hep B (Hepatitis B) (pediatric formulation)	Engerix B	Glaxo-SmithKline	<0.5
Hep B (Hepatitis B) (pediatric formulation)	Recombivax HB	Merck	0
Influenza	Fluzone³	Aventis Pasteur, Inc.	12.5
	Fluzone	Aventis Pasteur, Inc.	≤0.5ug/
	(Preservative Free)		0.25mL dose
Pneumococcal	Prevnar (pneumoconjugate)	Wyeth	0
IPV (Inactivated polio vaccine)	IPOL	Aventis Pasteur, SA	0
IPV (Inactivated polio vaccine)	Poliovax	Aventis Pasteur, Ltd.	0
MMR (Measles, mumps, and rubella)	MMR-II	Merck	0
Varicella	Varivax	Merck	0
¹Licensed for persons 7 years of age and older. ²For use in children 15 to 18 months of age. ³Influenza vaccine is recommended for children 6-23 months of age. MMWR (2004) 52:1-4; MMWR (2004) 53:1-3.

Page
184

Front Matter (R1-R14)

Executive Summary (1-20)

Immunization Safety Review: Vaccines and Autism (21-153)

References (154-164)

Appendix A: Committee Recommendations and Conclusions from Previous Reports (165-179)

Appendix B: Public Meeting Agenda, February 9, 2004 (180-182)

Appendix C: Thimerosal Content in Licensed Vaccines (183-186)

Appendix D: Chronology of Important Events Regarding Vaccine Safety (187-191)

Appendix E: Summary of Public Submissions (192-196)

Appendix F: Acronyms (197-200)

Free PDF Access

Free Resources

Related Titles

Immunization Safety Review: Vaccines and Autism (2004) Board on Health Promotion and Disease Prevention (HPDP) Institute of Medicine (IOM)

Citation Manager

Immunization Safety Review: Vaccines and Autism (2004)
Board on Health Promotion and Disease Prevention (HPDP)
Institute of Medicine (IOM)